Bullish
Anika Therapeutics' CEO, Stephen Griffin, acquired 12,200 shares of the company's common stock for $149,880 after a recent stock drop. This purchase i...
Anika Therapeutics' President and CEO, Stephen D. Griffin, purchased 12,200 shares of the company's common stock on April 30, 2026, at a weighted aver...
Bullish
Anika Therapeutics reported a robust Q1 2026 with revenue up 13% to $29.6 million and adjusted EBITDA climbing to $4.3 million, driven by strong growt...